HIV infection

Among SDNVP-exposed women initiating NNRTI-based ART, the proportion achieving viral suppression increased significantly with longer time since SDNVP exposure, from 37.5% at <6 months to 77.1% at >24

Effect: improvement; chi-square trend p=0.01

Among SDNVP-exposed women initiating NNRTI-based ART, the proportion achieving viral suppression increased significantly with longer time since SDNVP exposure, from 37.5% at <6 months to 77.1% at >24

Effect: improvement; chi-square trend p=0.01

Among SDNVP-exposed women initiating NNRTI-based ART, the proportion achieving viral suppression increased significantly with longer time since SDNVP exposure, from 37.5% at <6 months to 77.1% at >24

Effect: improvement; chi-square trend p=0.01

Among SDNVP-exposed women initiating NNRTI-based ART, the proportion achieving viral suppression increased significantly with longer time since SDNVP exposure, from 37.5% at <6 months to 77.1% at >24

Effect: improvement; chi-square trend p=0.01

Among SDNVP-exposed women initiating NNRTI-based ART, the proportion achieving viral suppression increased significantly with longer time since SDNVP exposure, from 37.5% at <6 months to 77.1% at >24

Effect: improvement; chi-square trend p=0.01

Among SDNVP-exposed women initiating NNRTI-based ART, the proportion achieving viral suppression increased significantly with longer time since SDNVP exposure, from 37.5% at <6 months to 77.1% at >24

Effect: improvement; chi-square trend p=0.01

Among SDNVP-exposed women initiating NNRTI-based ART, the proportion achieving viral suppression increased significantly with longer time since SDNVP exposure, from 37.5% at <6 months to 77.1% at >24

Effect: improvement; chi-square trend p=0.01

Among SDNVP-exposed women initiating NNRTI-based ART, the proportion achieving viral suppression increased significantly with longer time since SDNVP exposure, from 37.5% at <6 months to 77.1% at >24

Effect: improvement; chi-square trend p=0.01

Among SDNVP-exposed women initiating NNRTI-based ART, the proportion achieving viral suppression increased significantly with longer time since SDNVP exposure, from 37.5% at <6 months to 77.1% at >24

Effect: improvement; chi-square trend p=0.01

Among SDNVP-exposed women initiating NNRTI-based ART, the proportion achieving viral suppression increased significantly with longer time since SDNVP exposure, from 37.5% at <6 months to 77.1% at >24

Effect: improvement; chi-square trend p=0.01

Among SDNVP-exposed women initiating NNRTI-based ART, the proportion achieving viral suppression increased significantly with longer time since SDNVP exposure, from 37.5% at <6 months to 77.1% at >24

Effect: improvement; chi-square trend p=0.01

Among SDNVP-exposed women initiating NNRTI-based ART, the proportion achieving viral suppression increased significantly with longer time since SDNVP exposure, from 37.5% at <6 months to 77.1% at >24

Effect: improvement; chi-square trend p=0.01

Among SDNVP-exposed women initiating NNRTI-based ART, the proportion achieving viral suppression increased significantly with longer time since SDNVP exposure, from 37.5% at <6 months to 77.1% at >24

Effect: improvement; chi-square trend p=0.01

Among SDNVP-exposed women initiating NNRTI-based ART, the proportion achieving viral suppression increased significantly with longer time since SDNVP exposure, from 37.5% at <6 months to 77.1% at >24

Effect: improvement; chi-square trend p=0.01

Among SDNVP-exposed women initiating NNRTI-based ART, the proportion achieving viral suppression increased significantly with longer time since SDNVP exposure, from 37.5% at <6 months to 77.1% at >24

Effect: improvement; chi-square trend p=0.01

Among SDNVP-exposed women initiating NNRTI-based ART, the proportion achieving viral suppression increased significantly with longer time since SDNVP exposure, from 37.5% at <6 months to 77.1% at >24

Effect: improvement; chi-square trend p=0.01

Among SDNVP-exposed women initiating NNRTI-based ART, the proportion achieving viral suppression increased significantly with longer time since SDNVP exposure, from 37.5% at <6 months to 77.1% at >24

Effect: improvement; chi-square trend p=0.01

Among SDNVP-exposed women initiating NNRTI-based ART, the proportion achieving viral suppression increased significantly with longer time since SDNVP exposure, from 37.5% at <6 months to 77.1% at >24

Effect: improvement; chi-square trend p=0.01

Among SDNVP-exposed women initiating NNRTI-based ART, the proportion achieving viral suppression increased significantly with longer time since SDNVP exposure, from 37.5% at <6 months to 77.1% at >24

Effect: improvement; chi-square trend p=0.01

Among SDNVP-exposed women initiating NNRTI-based ART, the proportion achieving viral suppression increased significantly with longer time since SDNVP exposure, from 37.5% at <6 months to 77.1% at >24

Effect: improvement; chi-square trend p=0.01

Among SDNVP-exposed women initiating NNRTI-based ART, the proportion achieving viral suppression increased significantly with longer time since SDNVP exposure, from 37.5% at <6 months to 77.1% at >24

Effect: improvement; chi-square trend p=0.01

Among SDNVP-exposed women initiating NNRTI-based ART, the proportion achieving viral suppression increased significantly with longer time since SDNVP exposure, from 37.5% at <6 months to 77.1% at >24

Effect: improvement; chi-square trend p=0.01

Among SDNVP-exposed women initiating NNRTI-based ART, the proportion achieving viral suppression increased significantly with longer time since SDNVP exposure, from 37.5% at <6 months to 77.1% at >24

Effect: improvement; chi-square trend p=0.01

Among SDNVP-exposed women initiating NNRTI-based ART, the proportion achieving viral suppression increased significantly with longer time since SDNVP exposure, from 37.5% at <6 months to 77.1% at >24

Effect: improvement; chi-square trend p=0.01

Among SDNVP-exposed women initiating NNRTI-based ART, the proportion achieving viral suppression increased significantly with longer time since SDNVP exposure, from 37.5% at <6 months to 77.1% at >24

Effect: improvement; chi-square trend p=0.01

Among SDNVP-exposed women initiating NNRTI-based ART, the proportion achieving viral suppression increased significantly with longer time since SDNVP exposure, from 37.5% at <6 months to 77.1% at >24

Effect: improvement; chi-square trend p=0.01

Among SDNVP-exposed women initiating NNRTI-based ART, the proportion achieving viral suppression increased significantly with longer time since SDNVP exposure, from 37.5% at <6 months to 77.1% at >24

Effect: improvement; chi-square trend p=0.01

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91